In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation (vol 123, pg 85, 2017)

被引：1
|
作者：
Sager, Jennifer E. [1 ]
Tripathy, Sasmita [1 ]
Price, Lauren S. L. [1 ]
Nath, Abhinav [2 ]
Chang, Justine [3 ]
Stephenson-Famy, Alyssa [3 ]
Isoherranen, Nina [1 ]
机构：
[1] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA
[2] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA
来源：
BIOCHEMICAL PHARMACOLOGY | 2021年 / 183卷
关键词：
D O I：
10.1016/j.bcp.2020.114306
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Contribution of drug ionization to prediction of hepatic clearance and drug-drug interactions for CYP2D6
    Rougee, Luc R. A.
    Mohutsky, Michael A.
    Bedwell, David B.
    Ruterbories, Kenneth J.
    Hall, Stephen D.
    DRUG METABOLISM REVIEWS, 2016, 48 : 24 - 25
  • [22] Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6
    Bahar, Muh Akbar
    Setiawan, Didik
    Hak, Eelko
    Wilffert, Bob
    PHARMACOGENOMICS, 2017, 18 (07) : 701 - 743
  • [23] REVERSIBLE INTERACTION OF MOCLOBEMIDE WITH CYP2D6 AND CYP2C9
    GUENTERT, TW
    GRAM, LF
    GRANGE, S
    BROSEN, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 137 - 137
  • [24] Prediction of In Vivo Drug-Drug Interactions from In Vitro DataFactors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4
    Hayley S. Brown
    Aleksandra Galetin
    David Hallifax
    J. Brian Houston
    Clinical Pharmacokinetics, 2006, 45 : 1035 - 1050
  • [25] Exposure to oral oxycodone is increased by simultaneous inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone
    Gronlund, J.
    Hagelberg, N.
    Saari, T.
    Neuvonen, P.
    Olkkola, K.
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2010, 27 (01) : 144 - 144
  • [26] In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
    Xu, ZH
    Xie, HG
    Zhou, HH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (04) : 518 - 521
  • [27] Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions
    Huang, Weize
    Nakano, Mariko
    Sager, Jennifer
    Ragueneau-Majlessi, Isabelle
    Isoherranen, Nina
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (11) : 1156 - 1165
  • [28] More data for the CYP2D6 hypothesis?:: The in vivo inhibition of CYP2D6 isoenzyme and extrapyramidal symptoms induced by antidepressants in the elderly
    García-Parajuá, P
    de Ugarte, L
    Baca, E
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (01) : 111 - 112
  • [29] Prediction of in vivo drug-drug interactions from in vitro data -: Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4
    Brown, Hayley S.
    Galetin, Aleksandra
    Hallifax, David
    Houston, J. Brian
    CLINICAL PHARMACOKINETICS, 2006, 45 (10) : 1035 - 1050
  • [30] In vitro inhibition of CYP2D6 activity by fenfluramine.
    Marcucci, K
    Gotschall, R
    Kearns, GL
    Leeder, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 142 - 142
12345